Summary of Recommendations

Document Overview

Design and created by Guideline Central in participation with the European Society for Medical Oncology.

Management of Epithelial Ovarian Cancer

European Society for Medical Oncology

Publication Date: Jan 28, 2026

Page Last Updated: May 6, 2026

Levels of evidence and grades of recommendation

Levels of evidence	Description
I	Evidence from at least one large randomised, controlled trial of good methodological quality (low potential for bias) or meta-analyses of well-conducted randomised trials without heterogeneity
II	Small randomised trials or large randomised trials with a suspicion of bias (lower methodological quality) or meta-analyses of such trials or of trials demonstrated heterogeneity
III	Prospective cohort studies
IV	Retrospective cohort studies or case-control studies
V	Studies without control group, case reports, expert opinions
Grades of recommendation	Description
A	Strong evidence for efficacy with a substantial clinical benefit, strongly recommended
B	Strong or moderate evidence for efficacy but with a limited clinical benefit, generally recommended
C	Insufficient evidence for efficacy or benefit does not outweigh the risk or the disadvantages (adverse events, costs, etc.), optional
D	Moderate evidence against efficacy or for adverse outcome, generally not recommended
E	Strong evidence against efficacy or for adverse outcome, never recommended

Full Text Guideline: www.esmoopen.com/article/S2059-7029(25)01902-7/fulltext

Source Citation: A. González-Martín, J.A. Ledermann, ESMO Clinical Practice Guideline Express Update on the management of epithelial ovarian cancer, ESMO Open, 2026, 106032, ISSN 2059-7029, https://doi.org/10.1016/j.esmoop.2025.106032.

Document Objectives: This Express Update provides new recommendations for the following ESMO Clinical Practice Guideline (CPG): Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Diseases/Conditions (MeSH)

D010051 - Ovarian Neoplasms